Clinical Trial Update: Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

NCI-sponsored trial EP0057 (camptothecin nanoparticle) combined with olaparib in relapsed/refractory small cell lung cancer completed Phase 1/2, with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer
• Small Cell Lung Cancer
• Urothelial Carcinoma

Drugs mentioned

• EP0057 (camptothecin nanoparticle formulation)
• Olaparib (Olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Urothelial Carcinoma, Urothelial Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2025-07-09